Project Grant R01CA311526
Award Date 8/5/26
Completion Date 7/31/31
Dollars Obligated $637K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
University City, MO 63130, USA
Similar Awards
- The National Cancer Institute awarded The Washington University $623,616 on July 10, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to support development of PET imaging methods for detecting and quantifying CD163+ tumor-associated macrophages in head and neck cancer. The research addresses the role of tumor-associated macrophages (TAMs) in the tumor microenvironment, which coordinate angiogenesis, extracellular matrix remodeling, cancer cell proliferation,...
- The National Cancer Institute awarded The Washington University $659,087 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to support research targeting the NRF2 oxidative stress response pathway to sensitize head and neck squamous cell carcinoma (HNSCC) to immune checkpoint inhibitors. The research develops mechanistic understanding of how NRF2 pathway activation drives immune exclusion and resistance to anti-PD1 immunotherapy in HNSCC, which accounts for the sixth...
- The National Cancer Institute awarded Washington University $667,491 on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to conduct a multi-center investigation integrating positron emission tomography imaging and circulating tumor DNA analysis to predict response to PARP inhibitor therapy in metastatic castration-resistant prostate cancer patients. The recipient will lead a three-site imaging trial at Washington University School of Medicine, MD...
- The National Cancer Institute awarded The Washington University $641,419 on May 7, 2026, to fund clinical translation of a Meitner-Auger positron emission tomography (PET) theranostic agent for metastatic castrate-resistant prostate cancer (MCRPC), under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The work investigates first-in-man clinical imaging of a stable bromine-77 ligand, [77Br]Br-WC-DZ, that targets PARP1, an abundant genome-associated target in cancer cells. The...
- The National Cancer Institute awarded The Washington University $399,829 on May 13, 2026, under the Cancer Treatment Research program (CFDA 93.395) to mechanistically characterize a novel dendritic cell-based immunotherapy for solid tumors. The project will investigate how engineered dendritic cells expressing a B7H3-specific chimeric antigen receptor fused to toll-like receptor 4 signaling domains can overcome tumor immune tolerance by efficiently capturing tumor antigens and cross-priming...
- The National Cancer Institute awarded Washington University $562,550 on July 7, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop neoantigen-based spherical nucleic acid immunotherapeutics for triple negative breast cancer. The award funds development of a patient-specific nanoparticle immunotherapeutic, termed P-SNA, through an academic-industrial partnership between FlashPoint Therapeutics and the Gillanders Laboratory at Washington University School of Medicine. The...
- The National Institutes of Health National Cancer Institute awarded The Washington University $399,829 under the Cancer Treatment Research program (CFDA 93.395) on April 1, 2026, to conduct rational design of next-generation engineered T cells for enhanced cancer immunotherapy. The research addresses limited persistence of engineered T cells in cancer treatment by harnessing 4-1BB (CD137/TNFRSF9), a co-stimulatory molecule, through structure-informed protein design. Current 4-1BB chimeric...
- The National Cancer Institute awarded The Washington University $532,127 on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to evaluate the therapeutic index of TIP1-targeted beta and alpha radioimmunotherapy for non-small cell lung cancer treatment. The project develops and compares radiolabeled TIP1-targeted antibodies conjugated with alpha- and beta-emitting radionuclides to selectively deliver radiation to NSCLC tumor cells while minimizing off-target toxicity to...
- The National Cancer Institute awarded The Washington University $645,323 on July 10, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to conduct translational and clinical research on optimizing HER2 modulation in HER2-low breast tumors to enhance antibody-drug conjugate therapy. The research evaluates complementary biomarkers and therapeutic approaches to identify patients with HER2-low breast cancer who will respond to trastuzumab-deruxtecan (T-DXD) and to overcome...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Washington University a Project Grant totaling $3,182,665 (Award Date: September 24, 2025; Completion Date: August 31, 2029) under the Cancer Treatment Research program (CFDA 93.395) to investigate the role of natural killer (NK) cells in immune checkpoint therapy (ICT) of cancer. The research will elucidate the mechanisms by which NK cells constrain the effectiveness of ICT, evaluate the contribution of the NKG2D...